San Francisco startup Framework Therapeutics can be focusing on an oral, after-daily GLP-one drug identified as GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase examine showed average weight loss of close to 6% and it options to start out An additional mid-phase trial to the tip of the calendar year—that foun